Best Practices For Uptake and Use of Bispecific Therapy

EP: 1.Conditions for Administering Bispecific Therapy

EP: 2.Navigating Barriers Which Inhibit Optimal Use of Bispecifics

EP: 3.Key Decision Makers and Contributors Involved In Bispecific Administration

EP: 4.Pain Points In Bispecific Operationalization

EP: 5.Risk Evaluation and Mitigation Strategies [REMS] Program Considerations For Bispecific Therapy

EP: 6.Optimizing Bispecific Use Through EMR Utilization

Now Viewing

EP: 7.Best Practices For Uptake and Use of Bispecific Therapy

EP: 8.Achieving Seamless Care Transitions With Patients Receiving Bispecific Therapy

EP: 9.Intro to Bispecific Therapy: Implementation Essentials for Novice Institutions

EP: 10.Key Elements In Monitoring for Potential Adverse Events with Bispecific Antibodies

EP: 11.Protocol For Urgent and Around-the-Clock Bispecific Care

EP: 12.Obstacles to Optimal Transitions of Care Between Academic and Community Settings When Utilizing Bispecific Antibodies

EP: 13.Managed Care Considerations Within Bispecific Landscape

EP: 14.Payor-Provider Collaboration Driving Optimal Bispecific Therapy Strategies

EP: 15.Medication Assistance Programs Mitigating Financial Burden For Patients Receiving Bispecific Therapy

EP: 16.Bispecific Therapies: Current and Future Considerations

The following is a video synopsis/summary of a Peer Exchange involving Ryan Haumschild, PharmD, MS, MBA, CPEL; Kirollos Hanna, PharmD, BCPS, BCOP, FACCC; Sarah Rockwell, PharmD, BCOP; Melody Chang, RPh, MBA, BCOP; and Ryan Cain, PA-C.

This discussion illustrates the operational considerations and best practices for the use of bispecifics in treating lymphoma, myeloma, and other hematologic malignancies. The conversation covers the discrepancies in disease states, emphasizing the need to operationalize bispecifics based on the progression and severity of the disease. The importance of timely treatment, choosing between academic centers and local treatment, and considering patient demographics and travel restrictions are highlighted.

The discussion also delves into the unique considerations for different diseases, such as age-related factors in plasma cell disorders like myeloma. The focus on step-up dosing is explored, with insights into various approaches, including inpatient initiation and outpatient transition. The impact of bispecific agents on patients, particularly in terms of pharmacokinetics, dynamics, and the onset of CRS (cytokine release syndrome), is discussed. The emergence of leaders in the hematologic and oncology spaces incorporating step-up dosing into outpatient care is noted.

The experiences shared by healthcare professionals highlight the evolving landscape of treatment protocols and partnerships between community oncology and academic centers. The transcript emphasizes the need for communication, partnerships, and a warm handoff between institutions to ensure continuity of care for patients undergoing step-up dosing. The expansion of access to care through outpatient maintenance doses is considered a positive evolution in community oncology practices, showcasing adaptability to evolving treatment modalities. Overall, the conversation underscores the collaborative efforts in improving therapy success and patient outcomes in the realm of bispecific antibody treatments.

Video synopsis is AI-generated and reviewed by AJMC editorial staff.